CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
REGENERA evaluates the feasibility of C-MANF peptide as a treatment for amyotrophic lateral sclerosis (ALS), a severe neurodegenerative disease. This project aims to demonstrate C-MANF's protective effects on motoneurons, its ability to cross the blood-brain barrier, and its potential for cost-effective subcutaneous ad…
REGENERA will assess the technical and commercial feasibility of a novel and optimised C-MANF peptide as a superior treatment for amyotrophic lateral sclerosis (ALS). ALS is a fatal neurodegenerative disease affecting 450,000 people worldwide where motoneurons (MNs) selectively degenerate in the brain and spinal cord. ALS is characterised by muscle deterioration that rapidly leads to disability and culminates in death 3-5 years after diagnosis.
Unfortunately, there is no cure for ALS and current…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
